Day: September 23, 2021

Nouveau Monde Provides Update on the Deployment of its Fully Financed Phase-1 LiB Anode Material ProjectNouveau Monde Provides Update on the Deployment of its Fully Financed Phase-1 LiB Anode Material ProjectNouveau Monde is working to develop North America’s first fully vertically integrated production, from mining to the manufacturing of lithium-ion battery anode material With a projected 4,300 GWh of lithium-ion battery production capacity by 2030, demand for advanced materials is set to increase up to fivefold, with graphite as the lead mineral (Benchmark Mineral Intelligence, August 2021) Nouveau Monde is advancing its beneficiation production operations to support technical marketing and product qualification efforts Starting in 2022, Nouveau Monde is planning to produce several hundred tonnes of CSPG for qualification...

CELEBRATION, Fla., Sept. 23, 2021 (GLOBE NEWSWIRE) — KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that Travis C. Mickle, Ph.D., President and Chief Executive Officer of KemPharm, will present at the Cantor Fitzgerald Virtual Global Healthcare Conference taking place September 27-30, 2021. The live presentation will be available via webcast from the conference’s virtual platform. Details of the presentation are as follows:Event: Cantor Fitzgerald Virtual Global Healthcare ConferenceDate: September 28, 2021Time: 1:20 p.m., ETWebcast: https://wsw.com/webcast/cantor12/kmph/2086560Dr. Mickle and members of the KemPharm management team will host virtual one-on-one meetings with registered investors and pharmaceutical...

First Patient Infused with TIL Cell Therapy Manufactured at iCTC SAN CARLOS, Calif., Sept. 23, 2021 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), today reported that the Iovance Cell Therapy Center (iCTC) successfully manufactured and delivered the first clinical batch of TIL cell therapy LN-145. The first Iovance clinical study participant infused with LN-145 manufactured at iCTC is enrolled in a metastatic non-small cell lung cancer (mNSCLC) cohort in the IOV-COM-202 basket study in solid tumors. Igor Bilinsky, Ph.D., Chief Operating Officer of Iovance, stated, “We are thrilled to announce that one of our clinical study participants has received...

Dallas, Sept. 23, 2021 (GLOBE NEWSWIRE) — Thryv Holdings, Inc. (NASDAQ:THRY), the provider of Thryv® software, the leading end-to-end customer experience platform built for growing small businesses, today announced the launch of a Google My Business™ (GMB) Optimization add-on. The new feature helps small businesses get found online and chosen over their competition.  With a heavy emphasis on Google integrations within its software platform, including Reserve with Google, a centralized GMB dashboard, Gmail™ email service and more, Thryv has grown the number of connected GMB profiles from fewer than 1,000 to more than 30,000 connected profiles in the last two years.  A GMB listing is essential for small and medium businesses (SMBs) to survive. GMB contains vital information on a business that consumers will see when...

    Join us at the German Pavilion for the fourth annual China International Import Exposition (CIIE) in Shanghai from November 5-10, 2021. Hexagon Purus will showcase its world class cylinder and systems technologies for Fuel Cell Electric Vehicles (FCEVs) at CIIE 2021. CIIE is a premier exhibition that brings nation-wide market and government attention to international products and services. The Chinese government has developed a comprehensive plan to industrialize all key technologies to produce Fuel Cell Electric Vehicles (FCEVs) for mass market in the country. Their objective is to have 50,000 FCEVs on road by 2025, and 1 million after 2030. Most of these are expected to be light utility trucks, buses, and other commercial vehicles. But major Chinese OEMs are also targeting now the FC passenger car market in the second part of this...

MONTREAL, Sept. 23, 2021 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, today announced that it has entered into a definitive agreement with Incyte Biosciences International Sàrl, the Swiss-based affiliate of Incyte (NASDAQ:INCY), for the exclusive rights to distribute tafasitamab (sold as Monjuvi® in the United States and Minjuvi® in Europe) and pemigatinib (Pemazyre®) in Latin America. Under the terms of the agreement, Incyte will be responsible for the development, manufacture and supply to Knight of tafasitamab and pemigatinib, and Knight will be responsible for seeking the necessary regulatory approvals and distributing both medicines in Latin America. Tafasitamab in combination with lenalidomide is approved in the United States and Europe for the...

FORM 8.5 (EPT/RI)   PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY   1.        KEY INFORMATION  (a)        Name of exempt principal trader:Investec Bank plc(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offereeBlue Prism Group plc(c)        Name of the party to the offer with which exempt principal trader is connected:Investec is advisor and Joint broker to Blue Prism Group plcd)        Date dealing undertaken:8th September 2021(e)        Has the EPT previously disclosed, or is it today disclosing, in respect of any other party to this offer? No  2.        DEALINGS BY THE EXEMPT PRINCIPAL TRADER   (a)        Purchases and sales  Class...

Correction for date of KOL webcast Acacia Pharma to Report its Interim Results for the Six Months ended 30 June 2021 on 30 September 2021 Conference Call to be held on 30 September at 14.00 CEST/08.00 EST Cambridge, UK and Indianapolis, US – 23 September 2021, 13:00 CEST: Acacia Pharma Group plc (“Acacia Pharma” or the “Company”) (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or chemotherapy, announces that it will report its interim results for the half year ended 30 June 2021 at 07.00 CEST on Thursday 30 September. A presentation by Acacia Pharma’s senior management team will be webcast live the same day at 14.00 CEST (08.00 EST) and will include an...

ANN ARBOR, Mich., Sept. 23, 2021 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces today that it has delivered the first fabric samples to Spydasilk Enterprises (“Spydasilk”). These fabric blends will serve as the basis for developing the Company’s first line of recombinant spider silk apparel. Spydasilk, a Singapore-based joint venture between Kraig Labs and Kings Group, was formed to produce, market, and sell spider silk-based apparel into the ASEAN region. These first sample fabrics blend traditional silk with cotton to produce a composite, blended material in line with the design specification requested by the Kings Group’s lead designer. Once these sample fabrics have been tested...

NEW YORK, Sept. 23, 2021 (GLOBE NEWSWIRE) — Valley National Bancorp (“Valley”) (NASDAQ: VLY) and Bank Leumi Le-Israel Corporation (“Leumi”) announced today that they have entered into a definitive merger agreement whereby Valley will acquire Leumi, the US subsidiary of Bank Leumi Le-Israel B.M., and parent company of Bank Leumi USA (“Bank Leumi”). This strategic combination broadens Valley’s commercial product offerings and enhances Valley’s funding verticals. As a result of the mutually beneficial transaction, Valley will greatly expand its technology and venture capital banking business, and Bank Leumi Le-Israel B.M. will enhance its exposure to the U.S. banking market. This combination further solidifies Valley’s position as a top-tier, relationship-focused commercial bank. The pro forma company will be the 29th largest publicly...